Michael McCaughan
When Big Pharma executives looked at House Speaker Nancy Pelosi’s agenda for 2007, they didn’t see this coming.
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?
Michael McCaughan
When Big Pharma executives looked at House Speaker Nancy Pelosi’s agenda for 2007, they didn’t see this coming.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.